P Pfeiffer

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. doi request reprint Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Odense C, Denmark
    Ann Oncol 19:1141-5. 2008
  2. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
  3. ncbi request reprint Current role of antibody therapy in patients with metastatic colorectal cancer
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Odense C, Denmark
    Oncogene 26:3661-78. 2007
  4. doi request reprint Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
    C Qvortrup
    Department of Oncology, Odense University Hospital, Denmark
    Ann Oncol 19:1154-9. 2008
  5. doi request reprint A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer
    C Qvortrup
    Department of Oncology, Odense University Hospital, Sonder Boulevard 29, DK 5000 Odense C, Denmark
    Ann Oncol 21:87-91. 2010
  6. doi request reprint Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer
    D L Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Breast 21:556-61. 2012
  7. doi request reprint Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
    K R Schønnemann
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Eur J Cancer 48:510-7. 2012
  8. pmc Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
    K R Schønnemann
    Department of Oncology, Odense University Hospital, Odense C 5000, Denmark
    Br J Cancer 99:858-61. 2008
  9. ncbi request reprint Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer
    A Jakobsen
    Department of Oncology, Vejle Hospital, Denmark
    Acta Oncol 40:63-6. 2001
  10. ncbi request reprint Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2
    A M Gerdes
    Department of Clinical Genetics and Clinical Biochemistry, Odense University Hospital, Denmark
    Anticancer Res 18:2529-34. 1998

Collaborators

Detail Information

Publications26

  1. doi request reprint Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Odense C, Denmark
    Ann Oncol 19:1141-5. 2008
    ..Inspired by a pharmacokinetic study demonstrating no differences between weekly and biweekly cetuximab, we present the results of 74 consecutive patients treated with biweekly CetIri...
  2. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
    ....
  3. ncbi request reprint Current role of antibody therapy in patients with metastatic colorectal cancer
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Odense C, Denmark
    Oncogene 26:3661-78. 2007
    ..In this review, we summarize the current status of antibody therapy in patients with CRC...
  4. doi request reprint Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
    C Qvortrup
    Department of Oncology, Odense University Hospital, Denmark
    Ann Oncol 19:1154-9. 2008
    ..Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy...
  5. doi request reprint A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer
    C Qvortrup
    Department of Oncology, Odense University Hospital, Sonder Boulevard 29, DK 5000 Odense C, Denmark
    Ann Oncol 21:87-91. 2010
    ..In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity...
  6. doi request reprint Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer
    D L Nielsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Breast 21:556-61. 2012
    ..The aim was to evaluate activity and toxicity of hepatic arterial infusion of oxaliplatin in combination with capecitabine in patients with metastatic breast cancer with liver metastases and limited extrahepatic disease...
  7. doi request reprint Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
    K R Schønnemann
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Eur J Cancer 48:510-7. 2012
    ..The purpose of this phase II trial was to evaluate the efficacy and safety of cetuximab and irinotecan as second-line treatment in patients with gastro-oesophageal adenocarcinoma...
  8. pmc Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
    K R Schønnemann
    Department of Oncology, Odense University Hospital, Odense C 5000, Denmark
    Br J Cancer 99:858-61. 2008
    ..Neurotoxicity grade 2 was seen in 36.5%. We therefore conclude, that EXE every third week is a convenient regimen that easily can be administrated in the outpatient setting but the regimen needs further evaluation in a phase III study...
  9. ncbi request reprint Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer
    A Jakobsen
    Department of Oncology, Vejle Hospital, Denmark
    Acta Oncol 40:63-6. 2001
    ..8 months and the median crude survival was 11 months. In conclusion, hydroxyurea did not appear to increase either the response rate or the toxicity. Phase III trials along the same line cannot be recommended...
  10. ncbi request reprint Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2
    A M Gerdes
    Department of Clinical Genetics and Clinical Biochemistry, Odense University Hospital, Denmark
    Anticancer Res 18:2529-34. 1998
    ..This probably reflects that minor degrees of genetic aberrations are not sufficient to cause major biological disturbances, because regulatory cellular pathways are still operating...
  11. ncbi request reprint Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, DK 5000 Odense C, Denmark
    Eur J Cancer 42:2738-43. 2006
    ..We conclude that patients prefer the regimen with less toxicity and that it is of minor importance whether the medication is administrated orally at home or i.v. at the hospital...
  12. ncbi request reprint Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial
    O Hansen
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 35:57-61. 1996
    ..Moderate-dose S did not add to the antiemetic efficacy of M in non-cisplatin chemotherapeutic regimens...
  13. pmc Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Denmark
    Br J Cancer 78:96-9. 1998
    ..We conclude that evaluation of EGFR content using IHC and ELISA produces comparable results...
  14. doi request reprint Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
    J K Bjerregaard
    Department of Oncology, Odense University Hospital, Denmark
    Eur J Cancer 49:98-105. 2013
    ..Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC...
  15. ncbi request reprint Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Ann Oncol 17:252-8. 2006
    ..Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended...
  16. pmc Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Denmark
    Br J Cancer 74:86-91. 1996
    ..We conclude that immunohistochemical detection of these growth factor receptors failed to demonstrate a prognostic significance in patients operated on for NSCLC...
  17. ncbi request reprint Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
    P Pfeiffer
    Department of Oncology R, Odense University Hospital, Denmark
    Acta Oncol 31:219-24. 1992
    ....
  18. ncbi request reprint Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies
    M R Mirza
    Department of Oncology, Odense University Hospital, Denmark
    Acta Oncol 36:171-4. 1997
    ..We cannot recommend this drug for further clinical trials in NSCLC and ABC...
  19. ncbi request reprint Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature
    K Moeholt
    Department of Oncology, Aalborg Municipal Hospital, Denmark
    Acta Oncol 35:677-82. 1996
    ....
  20. ncbi request reprint Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study
    P Pfeiffer
    Department of Oncology, Odense University Hospital, Denmark
    Acta Oncol 29:171-3. 1990
    ..To overcome this problem, the oral medication should have a neutral taste, the solution should not be swallowed after the swishing, which should not be started until the nausea had ceased...
  21. ncbi request reprint A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients
    L Bastholt
    Dept of Oncology, Odense University Hospital, Denmark
    Cancer Chemother Pharmacol 28:205-10. 1991
    ..The modified plasma profile of the alkylating components following prednimustine administration may be important for the clinical efficacy of prednimustine...
  22. ncbi request reprint Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
    B Glimelius
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden
    Ann Oncol 13:1868-73. 2002
    ..This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer...
  23. doi request reprint A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
    B Glimelius
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden
    Ann Oncol 19:909-14. 2008
    ....
  24. ncbi request reprint Resectability of rectal cancers still fixed after radio-chemotherapy: evaluation by digital rectal examination, MRI, and intraoperative examination
    G Baatrup
    Department of Surgery, Section of Colorectal Surgery, Haukeland University Hospital, Bergen, Norway
    Int J Colorectal Dis 21:7-10. 2006
    ..After chemo-radiation DRE correctly predicted the tumor to be advanced or not in 12/17 patients, MRI in 14/17, and bimanual rectal examination in 17/17 patients...
  25. doi request reprint UFT (tegafur-uracil) in rectal cancer
    E Casado
    Department of Medical Oncology, Hospital Infanta Sofia, Madrid, Spain
    Ann Oncol 19:1371-8. 2008
    ..However, CI 5-FU is inconvenient for patients and is costly. Oral fluoropyrimidines like UFT (tegafur-uracil) offer a number of advantages over 5-FU...
  26. ncbi request reprint No evidence of gemcitabine accumulation during weekly administration
    S M De Lange
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Eur J Clin Pharmacol 61:843-9. 2005
    ..Gemcitabine can be administered safely without the risk that the drug will accumulate...